Our stock picking system has picked FORG (Forgent Networks  Inc.) today. The simulation software will buy this stock on July 06, 2006 at OPEN price. Our Loss Stop is at -28% Do not hold if stock drops more than 28%. Please visit us tomorrow after  9 o'clock for the next move.
 

Please see the below signals for the next trading day

RECENT PERFORMANCE
 

Dec 2005	21.6%
Jan 2006	41%
Feb 2006	-3.9%
Mar 2006	90%
Apr 2006	283%
May 2006	54.7%

COMPANY INFORMATION

Forgent Networks Inc.
108 Wild Basin Road
Austin, TX 78746
United States
Phone: 512-437-2700
Fax: 512-437-2792
Web Site: http://www.forgent.com
 

Sector:	Technology
Industry:	Business Software & Services
Full Time Employees:	33

Forgent Networks, Inc. operates as a licensor of intellectual property. It also provides scheduling and asset management software solutions that enable organizations to schedule and manage their office environment. The company’s intellectual property licensing business primarily includes a patent licensing program, which licenses its data compression technology. Forgent Networks’ software products include Meeting Room Manager, which provides a meeting logistics and room scheduling solution; Resource Scheduler, which allows businesses to schedule resources other than meeting rooms, such as shared equipment or other resources through an intuitive and customizable interface; and Visual Asset Manager, which enables companies to track and manage their fixed, mobile, and IT assets across the entire organization from any Web browser. The company also provides professional services for installation of and training on its software. It markets its products primarily small to medium-sized businesses and departments of enterprise organizations in the United States, Europe, and Asia Pacific. Forgent was founded in 1985 and is headquartered in Austin, Texas.

---

Genaera Corp.
5110 Campus Drive
Plymouth Meeting, PA 19462
United States
Phone: 610-941-4020
Fax: 610-941-5399
Web Site: http://www.genaera.com
 

Sector:	Healthcare
Industry:	Biotechnology
Full Time Employees:	46

Genaera Corporation, a biopharmaceutical company, engages in the research and development of medicines with focus on antiangiogenesis and respiratory diseases. The company’s primary product EVIZON is under Phase II and Phase III clinical trials to treat ophthalmic indications, specifically the ‘wet’ form of age related macular degeneration. It is also developing Squalamine Lactate, a Phase II clinical trail product, for the treatment of cancerous solid tumors; LOMUCIN, a Phase II clinical trail product, to treat the overproduction of mucus secretions involved in chronic respiratory disease; and interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma. In addition, the company has various discovery research programs focused on the treatment of obesity, infectious diseases, and inflammatory disorders. The company has a collaborative agreement with MedImmune, Inc. to develop and commercialize interleukin-9. Genaera Corporation was incorporated in 1987 and is headquartered in Plymouth Meeting, Pennsylvania.